HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buccheri, G. Articles by Ferrigno, D. Search for Related Content PubMed PubMed Citation Articles by Buccheri, G. Articles by Ferrigno, D. Related Collections Lung - cancer

Ann Thorac Surg 2003;75:973-980
© 2003 The Society of Thoracic Surgeons

---

Original article: general thoracic

Identifying patients at risk of early postoperative recurrence of lung cancer: a new use of the old CEA test

^a Cuneo Lung Cancer Study Group, Divisione di Pneumologia, Ospedale "S. Croce e Carle," Cuneo, Italy

Accepted for publication October 3, 2002.

^* Address reprint requests to Dr Buccheri, Divisione di Pneumologia, Ospedale "S. Croce e Carle," Cuneo I-12100, Italy.
e-mail: buccheri{at}culcasg.org

BACKGROUND: In the current study, we report the carcinoembryonic antigen (CEA) capability to predict early tumor relapses after a pulmonary resection for nonsmall cell lung cancer (NSCLC).

METHODS: We studied 118 consecutive NSCLC patients who were clinically judged operable and were eventually operated upon. Anthropometric, clinical, and CEA data along with the results of both preoperative and postoperative stage classifications were recorded. All patients were followed up for at least 1 year after surgery and the time to the first clinical recurrence recorded. Receiver-operating characteristic (ROC) curves and diagnostic formulas were used for data analysis.

RESULTS: In this series the CEA test was among the most accurate methods to predict an early postoperative recurrence (ROC area: 0.72, 95% confidence interval [CI]: 0.60 to 0.85, p = 0.001; accuracy rate for CEA at the threshold of 10 ng/mL: 83%, CI: 76% to 90%). Also predictive was the postoperative pathologic stage of disease (ROC area: 0.68, CI: 0.56 to 0.80, p = 0.007). In tumors pathologically classified in stage Ia to IIb, a preoperative CEA level higher than 10 ng/mL was associated with a 67% probability of tumor relapse. In the same stages of disease, a CEA level less than 10 ng/mL increased the baseline probability of no recurrence from 80% to 88%.

CONCLUSIONS: In operable patients with NSCLC the frequency of abnormal serum concentrations of CEA is low (17% in our series). However, it is important to identify such a small group of high-risk patients as many of them (in our study, 55% and 70% of those with a CEA value in excess of, respectively, 5 and 10 ng/mL) will develop an early postoperative recurrence. Such patients should be investigated preoperatively by mediastinoscopy or positron emission tomography in even in the absence of suspicious symptoms and signs. Then after an apparently successful operation, they should be carefully followed up. These patients could represent a suitable target for neoadjuvant clinical trials of selected high-risk groups.

This article has been cited by other articles:

				R. Kawachi, Y. Nakazato, H. Takei, Y. Koshi-ishi, and T. Goya Clinical significance of preoperative carcinoembryonic antigen level for clinical stage I non-small cell lung cancer: can preoperative carcinoembryonic antigen level predict pathological stage? Interactive CardioVascular and Thoracic Surgery, August 1, 2009; 9(2): 199 - 202. [Abstract] [Full Text] [PDF]

				J. Rubins, M. Unger, and G. L. Colice Follow-up and Surveillance of the Lung Cancer Patient Following Curative Intent Therapy: ACCP Evidence-Based Clinical Practice Guideline (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 355S - 367S. [Abstract] [Full Text] [PDF]

				T. Ohtsuka, K.-i. Watanabe, M. Kaji, T. Naruke, and K. Suemasu A clinicopathological study of resected pulmonary nodules with focal pure ground-glass opacity. Eur. J. Cardiothorac. Surg., July 1, 2006; 30(1): 160 - 163. [Abstract] [Full Text] [PDF]

				M. Inoue, M. Minami, H. Shiono, N. Sawabata, K. Ideguchi, and M. Okumura Clinicopathologic study of resected, peripheral, small-sized, non-small cell lung cancer tumors of 2 cm or less in diameter: Pleural invasion and increase of serum carcinoembryonic antigen level as predictors of nodal involvement J. Thorac. Cardiovasc. Surg., May 1, 2006; 131(5): 988 - 993. [Abstract] [Full Text] [PDF]

				A. Iwasaki, T. Shirakusa, Y. Yoshinaga, S. Enatsu, and M. Yamamoto Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor Eur. J. Cardiothorac. Surg., September 1, 2004; 26(3): 488 - 493. [Abstract] [Full Text] [PDF]

				Y. Sakao, S. Tomimitsu, Y. Takeda, M. Natsuaki, and T. Itoh Carcinoembryonic antigen as a predictive factor for postoperative tumor relapse in early-stage lung adenocarcinoma Eur. J. Cardiothorac. Surg., April 1, 2004; 25(4): 520 - 522. [Abstract] [Full Text] [PDF]

				N. Sawabata, M. Inoue, S.-i. Takeda, and H. Maeda Discrepancy in serum carcinoembryonic antigen levels by measuring kits Ann. Thorac. Surg., February 1, 2004; 77(2): 754 - 754. [Full Text] [PDF]

				G. Buccheri Discrepancy in serum carcinoembryonic antigen levels by measuring kits: Reply Ann. Thorac. Surg., February 1, 2004; 77(2): 754 - 754. [Full Text] [PDF]